Story perspectives
Trump's Return Puts Medicare Drug Pricing Negotiations at Risk
1/12/2025
50 6
1 of 1
Story summary
- Medicare's drug pricing negotiations, launched by President Biden, now hang in the balance as Trump prepares to take office. This initiative, designed to reduce costs for Medicare recipients, faces potential opposition from Trump’s allies. However, if negotiations continue, it could bolster Trump’s political standing, particularly with popular medications like Ozempic on the table.
